Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAIN2: Yiqi Huayu Jiedu Therapy in Hypertensive Intracerebral Hemorrhage
NCT07580235Not yet recruiting
- Sponsor
- Guangzhou University of Chinese Medicine
- Start
- Aug 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in intraparenchymal hematoma (IPH) comparing Yiqi Huayu Jiedu Mixture Intervention Group with Placebo Comparator Group (2 arms). Primary endpoint: Modified Rankin Scale score of 0-2 at 180 days. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
Yiqi Huayu Jiedu Mixture
03
Conditions
intraparenchymal hematoma (IPH)
Beyond the preview
Go deeper on NCT07580235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07580235.